The monotherapy group is essentially just more Vaxinia patients (albeit at a lower dose than MAST is currently at).
The timeline stated that the data update would be for early combo patients. Which makes sense, it's the combination of CF33-CD19 plus the CD19 directed therapy (blincyto) which we want to know about. That's what onCARlytics is.
Who knows what they mean in all those interviews. They've been saying that for years. Probably means that, for MAST trial, CF33 is finding and replicating in cancer cells, giving the clinical responses announced so far. For onCARlytics it might mean they are seeing clinical responses. Or it might just mean that the virus is causing CD19 to be expressed by cancer cells.
For me, further MAST trial data is much more overdue than onCARlytics. It's an open label trial, why do we have to wait so long for additional clinical responses to be announced?
IMU Price at posting:
3.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)